Attached files
| file | filename |
|---|---|
| EX-99 - LETTER FROM MALONEBAILEY LLP TO THE BOARD OF DIRECTORS - VASO Corp | vaso_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report: March 30, 2020
(Date
of earliest event reported)
VASO CORPORATION
(Exact
name of registrant as specified in charter)
|
Delaware
|
|
0-18105
|
|
11-2871434
|
|
(State
or other jurisdiction
|
|
(Commission
File
|
|
(IRS
Employer
|
|
of
incorporation)
|
|
Number)
|
|
Identification
No.)
|
|
137
Commercial Street, Suite 200, Plainview, New York
|
|
11803
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (516)
997-4600
.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
to communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
Securities
registered or to be registered pursuant to Section 12(b) of the
Act:
|
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accountant standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 8.01 – OTHER EVENTS
In
accordance with the Securities and Exchange Commission (the
“SEC”) Order Under Section 36 of the Securities
Exchange Act of 1934 Granting Exemptions from Specified Provisions
of the Exchange Act and Certain Rules Thereunder, SEC Release No.
34-88318, dated March 4, 2020 (the “Order”), Vaso
Corporation (the “Company”) hereby states the
following:
●
The Company is
relying on the relief provided by the Order in connection with the
filing of its Annual Report on Form 10-K for the year ended
December 31, 2019 (the “Annual Report”).
●
The delay in filing
is due to staffing difficulties by both the Company and the
auditors as a result of the COVID-19 pandemic, materially impairing
the Company’s ability to file its Annual Report by March 30,
2020. The Company’s principal offices, including its
accounting department, are located in Nassau County, New York,
which area has been significantly impacted by the coronavirus.
Attached is a letter from the Company’s auditors,
MaloneBailey LLP, in support of this position.
●
The Company
currently expects to file the Annual Report on or before April 20,
2020, but in any event no later than 45 days after the original due
date for the Annual Report.
Forward-Looking Statements
Forward looking statements in this document are made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Except for historical information contained in this report, the
matters discussed are forward-looking statements that involve risks
and uncertainties, including but not limited to the spread of
COVID-19 and governmental and industry response thereto. When used
in this report, words such as “anticipates”,
“believes”, “could”,
“estimates”, “expects”, “may”,
“plans”, “potential” and
“intends” and similar expressions, as they relate to
the Company or its management, identify forward-looking statements.
Such forward-looking statements are based on the beliefs of the
Company’s management, as well as assumptions made by and
information currently available to the Company’s management.
Among the factors that could cause actual results to differ
materially are the following: the effect of business and economic
conditions; the effect of the dramatic changes taking place in IT
and healthcare; continuation of the General Electric Healthcare
agreements; the impact of competitive technology and products and
their pricing; medical insurance reimbursement policies; unexpected
manufacturing or supplier problems; unforeseen difficulties and
delays in the conduct of product development programs; the actions
of regulatory authorities and third-party payers in the United
States and overseas; and the risk factors reported from time to
time in the Company’s SEC reports. The Company undertakes no
obligation to update forward-looking statements as a result of
future events or developments.
2
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d)
Exhibits.
|
Exhibit No.
|
|
Description
|
|
|
Letter from
MaloneBailey LLP to the Board of Directors of Vaso Corporation
dated March 26, 2020.
|
3
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
VASO CORPORATION
|
|
|
|
|
|
|
|
|
Date: March
30, 2020
|
By:
|
/s/ Jun Ma
|
|
|
|
|
Jun Ma
|
|
|
|
|
Chief
Executive Officer and President
|
|
4